Table 2.
Characteristics | Patients treated with daptomycin | ||
---|---|---|---|
RIE N = 149 |
LIE N = 414 |
BRLIE N = 47 |
|
Age (years) | |||
Median (range) | 58.0 (1–90) | 62.0 (10–91) | 63.0 (24–87) |
<65, n (%) | 93 (62.4) | 227 (54.8) | 25 (53.2) |
≥65, n (%) | 56 (37.6) | 187 (45.2) | 22 (46.8) |
≥75, n (%) | 28 (18.8) | 82 (19.8) | 16 (34.0) |
Sex, n (%) | |||
Female | 45 (30.2) | 154 (37.2) | 17 (36.2) |
Male | 104 (69.8) | 260 (62.8) | 30 (63.8) |
Race, n (%) | |||
Caucasian | 124 (83.2) | 355 (85.7) | 40 (85.1) |
Othera | 14 (9.4) | 28 (6.8) | 2 (4.3) |
Unknown | 11 (7.4) | 31 (7.5) | 5 (10.6) |
Body weight (kg) | |||
Median (range) | 68.0 (6–98) | 73.0 (25–120) | 70.0 (43–93) |
Setting prior to daptomycin therapy, n (%) | |||
Hospital | 133 (89.3) | 389 (94.0) | 43 (91.5) |
Nursing home/extended care | – | – | 1 (2.1) |
Community | 14 (9.4) | 24 (5.8) | 2 (4.3) |
Unknown | – | – | 1 (2.1) |
Other | 2 (1.3) | 1 (0.2) | – |
Received HMG-CoA reductase inhibitor (statin) with daptomycin, n (%) | |||
Yes | 19 (12.8) | 59 (14.3) | 3 (6.4) |
No | 129 (86.6) | 354 (85.5) | 44 (93.6) |
Unknown | 1 (0.7) | 1 (0.2) | – |
Severe renal impairment (CrCl <30 mL/min) at initiation of daptomycin therapy, n (%) | 18 (12.1) | 76 (18.4) | 8 (17.0) |
Patients on dialysis at daptomycin initiation, n (%) | 13 (8.7) | 51 (12.3) | 6 (12.8) |
Any significant underlying diseases (>10% of patients in every group), n (%) | 133 (89.3) | 378 (91.3) | 43 (91.5) |
Cardiovascular disease | 93 (62.4) | 322 (77.8) | 34 (72.3) |
Gastrointestinal disease | 24 (16.1) | 55 (13.3) | 7 (14.9) |
Pulmonary disease | 21 (14.1) | 51 (12.3) | 9 (19.1) |
Renal disease | 25 (16.8) | 83 (20.0) | 12 (25.5) |
BRLIE both right- and left-sided infective endocarditis, CrCl creatinine clearance, HMG-CoA 3-hydroxy-3-methylglutaryl-coenzyme A, LIE left-sided infective endocarditis, RIE right-sided infective endocarditis, SD standard deviation
aAsian, Black and missing